Eccogene Raises Cny 180 Million In Series B Equity Financing, Propelling Its Pipeline Of Treatments For Metabolic Diseases
Eccogene Raises Cny 180 Million In Series B Equity Financing, Propelling Its Pipeline Of Treatments For Metabolic Diseases
06/12/23, 12:00 AM
Location
shanghaiMoney raised
¥180 million
Industry
biopharma
therapeutics
biotechnology
health care
Round Type
series b
Investors
Qingsong Capital, Oriza Seed Capital, Delos Capital, Elikon Venture, Huajin Capital, Yu Fu Investment, Rockbleu Capital, Zhangjiang Healthcare Venture Capital, New Alliance Capital
Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY 180 million (about $25 million) Series B financing. The financing was co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital. The syndicate also included new investors Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture and existing investors Delos Capital, Oriza Seed Capital and Qingsong Capital. The proceeds from the financing will be used to support the development of Eccogene's clinical-stage programs including the Phase I trial of ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the Phase I trial of ECC4703, a THRb full agonist for NASH and lipid disorders, as well as to further advance Eccogene's preclinical programs for metabolic and immunological diseases.
Company Info
Location
shanghai, shanghai, china
Additional Info
Eccogene is a biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases.
Eccogene is specialized in disease biology, medicinal chemistry, and translational science to advance its novel and differentiated pipeline of drugs to address the unmet medical needs for metabolic and immune-related diseases.